M. H. Ryu - Dept Oncol, Asan Med Ctr

基本信息

浏览量：35

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 99 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

1075TiP A phase I/Ib open-label, first-in-human, single agent, dose escalation and expansion study of a HER2-targeted T cell engager (SAR443216) in patients with relapsed/refractory HER2-expressing solid tumors

E.E. Dumbrava, E. Calvo,E. Garralda,M.H. Ryu, D-Y. Oh,L-Y. Bai,W. Chung,K.I. Rojas Laimito,O. Yildirim,S. Masciari, K. Kang, B. Buday, F. Rharbaoui,G. Abbadessa,V. Moreno Garcia

Annals of Oncology (2023): S647-S647

引用0浏览0引用

The HER2-targeting ADC SHR-A1811 in HER2-expressing/mutated advanced non-breast solid tumors (STs): Results from the global phase I study

H. Yao,M. H. Ryu, J. Park,M. Voskoboynik, J. H. Kim, K. Liu,M. Barve, A. Acuna-Villaorduna,S-A. Im, A. C. Roy,L-Y. Bai,C-J. Yen, J. Zhang,V. Ganju, L. Wu, M. Yan, L. Bao, Y. Zhao, S. Rong,E. Song

ANNALS OF ONCOLOGY（2023）

引用0浏览0引用

656MO the HER2-targeting ADC SHR-A1811 in HER2-expressing/mutated Advanced Non-Breast Solid Tumors (sts): Results from the Global Phase I Study

H. Yao,M.H. Ryu,J. Park,M. Voskoboynik,J.H. Kim, K. Liu,M. Barve, A. Acuna-Villaorduna, S-A. Im,A.C. Roy,L-Y. Bai,C-J. Yen,J. Zhang,V. Ganju, L. Wu, M. Yan,L. Bao,Y. Zhao, S. Rong,E. Song

Annals of Oncology (2023): S461-S462

引用2浏览0引用

Phase II Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on First-Line Atezolizumab Plus Bevacizumab: REGONEXT Trial

J. Cheon,B-Y. Ryoo,H-D. Kim,K-P. Kim,M. H. Ryu,H. J. Chon,B. Kang,R. S. Finn,C. Yoo

Journal of clinical oncologyno. 4_suppl (2023): TPS634-TPS634

引用0浏览0引用

Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study

S. Y. Rha,L. S. Wyrwicz, P. E. Y. Weber, Y. Bai,M. H. Ryu,J. Lee,F. Rivera,G. V. Alves,M. Garrido,K. -k. Shiu,M. Gonzalez Fernandez, J. Li,M. Lowery,T. Cil,F. J. S. M. Cruz,S. Qin, L. Yin,S. Bordia,P. Bhagia,D-y. Oh

ANNALS OF ONCOLOGY（2023）

引用9浏览0引用

Pembrolizumab (Pembro) or placebo (Pbo) plus chemotherapy (Chemo) for advanced HER2-negative gastric/gastroesophageal junction (G/GEJ) adenocarcinoma (KEYNOTE-859): Asia subgroup analysis

D-Y. Oh, Y. Bai,M. H. Ryu, J. Lee, J. Li, S. Luo, H. Pan,Y. Qu, J. Lu, L. Yang,H. Yasui,H. Yabusaki,C. J. Yen,W. W. L. Chan, K. Yamaguchi,K-H. Yeh, L. Yin,S. Bordia,P. Bhagia,S. Y. Rha

ANNALS OF ONCOLOGY (2023): S1526-S1526

引用0浏览0引用

VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study

S.Y. Rha,L.S. Wyrwicz, P.E.Y. Weber, Y. Bai,M.H. Ryu,J. Lee,F. Rivera,G.V. Alves,M. Garrido,K-K. Shiu,M. González Fernández, J. Li,M. Lowery,T. Cil,F.J.S.M. Cruz,S. Qin, L. Yin,S. Bordia,P. Bhagia, D-Y. Oh

Annals of Oncologyno. 3 (2023): 319-320

引用22浏览0引用

1237P Phase I Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Rivoceranib Plus Paclitaxel in Advanced Gastric or Gastroesophageal Junction (GEJ) Cancer

M. H. Ryu, A. Pande, J. H. Kim,Y-K. Kang

ANNALS OF ONCOLOGYno. 7 (2022): S1114-S1114

引用0浏览0引用

1374P A Randomized Phase III Study to Compare Efficacy and Safety Between Combination Therapy and Monotherapy As First-Line Chemotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10)

I. Choi,K-W. Lee,D. Y. Zang,M. H. Ryu, H. S. Han, K. H. Kim,M-J. Kim,S. A. Koh, S. S. Lee,D-H. Koo,Y. H. Ko,B. S. Sohn, J. H. Park, J. W. Kim

Annals of oncology（2021）

引用1浏览0引用

LBA7_PR Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Patients with Previously Untreated Advanced or Recurrent Gastric/gastroesophageal Junction (G/GEJ) Cancer: ATTRACTION-4 (ONO-4538-37) Study

N. Boku,M. H. Ryu,D-Y. Oh,S. C. Oh,H. C. Chung,K-W. Lee,T. Omori,K. Shitara,S. Sakuramoto,I. J. Chung, K. Yamaguchi, K. Kato,S. J. Sym,S. Kadowaki, K. Tsuji,J-S. Chen,L-Y. Bai,L-T. Chen,Y-K. Kang

Annals of oncology（2020）

引用135浏览0引用

135

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn